Who funds HIV research?

We count 277 funded HIV projects, active between 2020 and 2035, from 6 funders. The most came from NIH · NIAID (97 projects), Gates Foundation (51 projects) and Wellcome (40 projects). The median award is $3.6M, across the 269 of 277 projects that list an amount.

Funded projects

277

Funders

6

Median award

$3.6M

Open calls now

14

Top funders of HIV research

Projects whose title or summary mentions HIV. Median award: of the projects that list an amount, in US dollars; “—” when fewer than 3 do.

Open HIV funding calls

14 open calls mention HIV today; the 12 most on-topic are listed.

• High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
  National Institutes of HealthUp to $1,500,000Deadline: March 5, 2027 ·
• High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
  National Institutes of HealthNot specifiedDeadline: March 6, 2027 ·
  Real odds: About 1 in 8 funded (13% · NIH R01-equivalent grants, all NIH institutes, FY2025)
• Centers for Structural Biology of HIV and Other Infectious Diseases (U54 Clinical Trial Not Allowed)
  National Institutes of HealthUp to $3,500,000Deadline: May 28, 2027 ·
• Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)
  National Institutes of HealthNot specifiedDeadline: October 28, 2027 ·
• Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)
  National Institutes of HealthNot specifiedDeadline: November 16, 2027 ·
  Real odds: About 1 in 9 funded (11% · NIH R21 (exploratory/developmental), all NIH institutes, FY2025)
• Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
  National Institutes of HealthNot specifiedDeadline: September 25, 2028 ·
• Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)
  National Institutes of HealthNot specifiedDeadline: June 20, 2029 ·
• Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Intervention and Services Research Trials (R34 Clinical Trial Optional)
  National Institutes of HealthUp to $450,000Deadline: July 16, 2029 ·
• Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)
  National Institutes of HealthNot specifiedDeadline: December 3, 2027 ·
  Real odds: About 1 in 8 funded (13% · NIH R01-equivalent grants, all NIH institutes, FY2025)
• Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
  National Institutes of HealthNot specifiedDeadline: December 3, 2027 ·
  Real odds: About 1 in 9 funded (11% · NIH R21 (exploratory/developmental), all NIH institutes, FY2025)
• Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 CT Not Allowed)
  National Institutes of HealthUp to $200,000Deadline: October 20, 2028 ·
  Real odds: About 1 in 9 funded (11% · NIH R21 (exploratory/developmental), all NIH institutes, FY2025)
• Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)
  National Institutes of HealthUp to $400,000Deadline: November 5, 2028 ·
  Real odds: About 1 in 8 funded (13% · NIH R01-equivalent grants, all NIH institutes, FY2025)

Real odds

• About 1 in 8 funded · 13% · NIH R01-equivalent grants, all NIH institutes, FY2025 · NIH Data Book, report 29
• About 1 in 9 funded · 11% · NIH R21 (exploratory/developmental), all NIH institutes, FY2025 · NIH Data Book, report 202

Published success rates for the programs behind the open calls above: the share of applications the funder funded, program-wide, not for this topic.

Forecast: announced, not open yet

13 forecast calls on HIV. Funders publish forecasts before a call opens; you can't apply to these yet, and dates can change.

• ForecastHIV Care Grant Program - Part B States/Territories Formula and AIDS Drug Assistance Program Formula and AIDS Drug Assistance Program Supplemental Awards
  Health Resources and Services AdministrationNot specifiedExpected to open October 31, 2026
• ForecastHIV Care Grant Program - Part B States/Territories Formula and AIDS Drug Assistance Program Formula and AIDS Drug Assistance Program Supplemental Awards: Pacific Islands Jurisdictions
  Health Resources and Services AdministrationNot specifiedExpected to open October 31, 2026
• ForecastDemonstration Projects for Whole-Person Health Models for Women Living with HIV in the South
  Centers for Disease Control - NCHHSTPNot specifiedExpected to open January 14, 2027
• ForecastSingle Cell Opioid Responses in the Context of HIV (SCORCH) Program: Phase 2
  National Institutes of HealthUp to $1,000,000Expected to open February 1, 2027
• ForecastDirect-to-Consumer Distribution of HIV and other STI Self-Tests
  Centers for Disease Control - NCHHSTPNot specifiedExpected to open March 22, 2027
• ForecastHIV Prevention and Alcohol (R61/R33 Clinical Trials Optional)
  National Institutes of HealthNot specifiedExpected to open July 7, 2027
• ForecastLeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE)
  National Institutes of HealthNot specifiedExpected to open July 20, 2027
• ForecastPrevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource-Constrained Settings--Implementation Science Network (PATC3H-IN)
  National Institutes of HealthNot specifiedExpected to open July 24, 2027

Funded HIV projects

A sample, latest start first, at most three per program.

• Support for Correlates of Protection efforts associated with the C113 phase 2b trial of MTBVAC in IGRA+, HIV- African adults and adolescents
  Wellcome · £2,283,453 · ends 2035
• Strengthening Adolescent Resilience to Improve Sexual and reproductive hEalth (ARISE) Uganda
  Wellcome · £3,385,545 · ends 2034
• Resolving HIV-1 transport and host cofactor regulation in the cellular context
  Wellcome · £4,774,316 · ends 2033
• MWCCS Northwestern University MORE: Multi-omics for HIV/AIDS Aging Research
  NIH · NHLBI · $3,177,306 · ends 2032
• Miami MACS-WIHS Combined Cohort Study Clinical Research Site
  NIH · NHLBI · $3,131,404 · ends 2032
• MWCCS UAB/UMMC Clinical Research Site
  NIH · NHLBI · $3,315,025 · ends 2032
• CFAR Network of Integrated Clinical Systems (CNICS)
  NIH · NIAID · $8,393,612 · ends 2031
• HIV and Other Infectious Diseases Clinical Research Support Services (CRSS)
  NIH · NIAID · $8,460,011 · ends 2031
• The University of North Carolina Center for AIDS Research
  NIH · NIAID · $3,155,764 · ends 2031
• Fred Hutchinson Cancer Center — Create Novel Technology Platform Capabilities
  Gates Foundation · $3,948,797 · ends 2031

How we count

Funded projects come from public award records (NIH RePORTER, NSF, EU CORDIS, UKRI Gateway to Research, Wellcome, the Gates Foundation, DOE, NASA and USDA NIFA) whose title or summary matches “hiv”. NIH lists each budget year separately; one project counts once. Amounts are as the funder lists them; medians use only projects that list one, in US dollars. Open calls and forecasts are from our listings of October 28, 2026. A project can mention a topic without being mainly about it, so treat the counts as a guide to who funds the area.